Non-motor Symptoms and Brain Dopamine Transporter Binding
NCT ID: NCT02650843
Last Updated: 2025-04-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
455 participants
OBSERVATIONAL
2015-01-31
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty
NCT00129675
Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls
NCT01461109
PET Study of Non-Motor Symptoms of Parkinson Disease
NCT01565473
DAT SPECT and Procedural Motor Skills in Parkinson's Disease
NCT03076307
Prognostic Value of FP-CIT-SPECT in Parkinson´s Disease
NCT01038310
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with parkinsonism
Patients with parkinsonism that are referred for DAT SPECT imaging in Turku University Hospital, Finland or Helsinki University Hospital, Finland
DAT SPECT imaging
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DAT SPECT imaging
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-100 years
* Referred for clinical DAT SPECT in Turku or Helsinki
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Helsinki University Central Hospital
OTHER
Turku University Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
References
Explore related publications, articles, or registry entries linked to this study.
Eklund M, Nuuttila S, Joutsa J, Jaakkola E, Makinen E, Honkanen EA, Lindholm K, Vahlberg T, Noponen T, Ihalainen T, Murtomaki K, Nojonen T, Levo R, Mertsalmi T, Scheperjans F, Kaasinen V. Diagnostic value of micrographia in Parkinson's disease: a study with [123I]FP-CIT SPECT. J Neural Transm (Vienna). 2022 Jul;129(7):895-904. doi: 10.1007/s00702-022-02517-1. Epub 2022 May 27.
Nuuttila S, Eklund M, Joutsa J, Jaakkola E, Makinen E, Honkanen EA, Lindholm K, Noponen T, Ihalainen T, Murtomaki K, Nojonen T, Levo R, Mertsalmi T, Scheperjans F, Kaasinen V. Diagnostic accuracy of glabellar tap sign for Parkinson's disease. J Neural Transm (Vienna). 2021 Nov;128(11):1655-1661. doi: 10.1007/s00702-021-02391-3. Epub 2021 Jul 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T12/2014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.